This additional application, supported by data from the GWPCARE6 trial, seeks to expand the indication of cannabidiol to include seizures associated with tuberous sclerosis complex.
from Front page feed https://ift.tt/2SpLAdW
from Front page feed https://ift.tt/2SpLAdW
Comments
Post a Comment